Assessment of signaling pathway inhibitors and identification of predictive biomarkers in malignant pleural mesothelioma

Malignant pleural mesothelioma (MPM) is a rare tumor principally due to past exposure to asbestos, a carcinogenic natural mineral fiber that induces genomic and genetic alterations [1]. Lack of curative treatment due to resistance to anti-cancer therapies combined with tumor aggressiveness accounts for the poor prognosis associated to MPM. Despite the significant advances in oncotherapy, MPM is still a challenging cancer to treat [2].
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research

Related Links:

Conclusion: The approaches of this review are to highlight the recent management advances and contrast the differences of treatment practice between Western and Asian countries.
Source: Current Cancer Therapy Reviews - Category: Cancer & Oncology Source Type: research
Scientists at the Vaccine and Immunotherapy Center (VIC) at Massachusetts General Hospital have uncovered a novel, two-agent immunotherapy combination that worked surprisingly well in animal models with malignant mesothelioma. The discovery has sparked new optimism for immunotherapy, which has struggled to provide consistently positive results with aggressive cancers such as mesothelioma. “This is the beginning of a new story of hope, a new combination of immunotherapy,” Dr. Mark Poznansky, director of the VIC and associate professor at Harvard Medical School, told Asbestos.com. “It worked quite well in a...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Shares in Novocure (NSDQ:NVCR) are on the rise today after the medical device maker topped revenue and losses-per-share expectations on Wall Street with its 3rd quarter earnings results. The St. Helier, N.J.-based company posted losses of $11.5 million, or 13¢ per share, on sales of $50.1 million for the 3 months ended September 30, seeing losses on the bottom-line shrink 65.8% while sales grew 131.2% compared with the same period during the previous fiscal year. Losses per share for the quarter came in under the 17¢ consensus on Wall Street, while sales beat the $43.6 million expectations on The Street. &ld...
Source: Mass Device - Category: Medical Devices Authors: Tags: Business/Financial News MassDevice Earnings Roundup NovoCure Source Type: news
Treatment options for malignant mesothelioma may soon include customized gene therapy, according to thoracic surgeon and scientist Dr. Prasad Adusumilli at Memorial Sloan Kettering Cancer Center in New York. Gene therapy involves a laboratory reprogramming of a patient’s own T cells, which are a type of white blood cell, to recognize and destroy the cancer. The U.S. Food and Drug Administration (FDA) recently approved the first gene therapy specifically for pediatric leukemia, signaling the start of a new approach to cancer treatment in this country. The newly approved treatment is also known as chimeric antigen rece...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: CAR T cell therapy checkpoint blockade chimeric antigen receptor T cell therapy Dr. Andy Haas Dr. Prasad Adusumilli Dr. Scott Gottlieb FDA Commissioner gene therapy cancer gene therapy for mesothelioma immunotherapy clinical trial mali Source Type: news
Cancer patients who opt for alternative therapy instead of conventional medicine significantly decrease their chances of survival, according to researchers at Yale School of Medicine. Although the popularity of alternative medicine continues to grow, a recent study published in the Journal of the National Cancer Institute found survival rates significantly reduced for those who use it as first-line therapy. Conventional cancer treatments — chemotherapy, surgery and radiation — still produce a much better chance of survival. Mesothelioma was not included in the study, but the findings are relevant to this rare ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: acupuncture cancer Alternative medicine alternative mesothelioma treatment alternative therapy survival alternative vs conventional medicine breast cancer colon cancer Conventional cancer treatments Dr. David Gorski Dr. Skyler Johnson Source Type: news
Authors: Rimkus T, Sirkisoon S, Harrison A, Lo HW Abstract Tumor suppressor candidate 2 (TUSC2, also known as FUS1) was identified in 2000 as a candidate tumor suppressor gene located in a region on chromosome 3p21.3 that is homozygously deleted in some lung and breast cancers. The deletion is rare in lung and breast cancers, but is frequent in malignant pleural mesothelioma. Evidence to date indicates that TUSC2 behaves as a tumor suppressor in lung cancer; however, its role as a tumor suppressor for other tumor types has not been fully established. Loss of TUSC2 expression at the mRNA and protein levels has been ...
Source: Discovery Medicine - Category: Research Tags: Discov Med Source Type: research
This study is part of a broad development program that includes a number of additional planned studies." TRACON Pharmaceuticals develops novel targeted cancer therapies. Its TRC105 antibody is directed at renal cell carcinoma and hepatocellular carcinoma. This clinical trial with TRC102 is one of five nationally involving methoxyamine, but one of more than 200 trials for mesothelioma.
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Research & Clinical Trials Source Type: news
Thoracic surgeon and robotics innovator Dr. Farid Gharagozloo believes regular early screenings and better follow-up care will significantly reduce the annual number of Americans dying of lung cancer by almost two-thirds. Gharagozloo, director of cardiothoracic surgery at Florida Hospital Celebration Health, says the medical establishment in the U.S. and patients themselves share the blame for the unreasonably high number of lung cancer deaths today. Patients need to be more assertive. Doctors need to be more aggressive. Together, they can make a big difference. "We can turn this thing around — change the who...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Treatment & Doctors Source Type: news
The U.S. Food and Drug Administration (FDA) recently granted approval for immunotherapy drugs Keytruda and Opdivo to fight non-small cell lung cancer, raising the hopes of patients with malignant pleural mesothelioma. Drugmakers Merck &Co. and Bristol-Myers Squibb manufacture Keytruda (pembrolizumab) and Opdivo (nivolumab), respectively. Both drugs target PD-1 and PD-L1, specific proteins that block a body's immune system from attacking the cancer cells. Those same proteins were identified in a subset of mesothelioma patients with the shortest survival times. The University of Chicago Comprehensive Cancer Center re...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: Treatment & Doctors Source Type: news
MicroRNA expression is commonly suppressed in cancer, contributing to tumor cell biology. Recently we demonstrated that multiple members of the miR-15/16 family are downregulated and have tumor suppressor functions in malignant pleural mesothelioma (MPM), an asbestos-related cancer for which few treatments are available. These results are similar to previous findings in prostate and non-small cell lung cancer (NSCLC). Using mimics to restore levels of miR 15a, miR-15b or miR-16 led to growth inhibition and induction of apoptosis of MPM cells in vitro. The miR-16 mimic, packaged in bacterially-derived, EGFR antibody-targete...
Source: Cancer Research - Category: Cancer & Oncology Authors: Tags: Molecular and Cellular Biology Source Type: research
More News: Asbestosis | Cancer | Cancer & Oncology | Cancer Therapy | Genetics | Lung Cancer | Mesothelioma